sintilimab,anlotinib
eli lilly,advenchen,sino biopharmaceuticals
['sclc', 'lcsm,(-blcsm)', 'anlotinib', 'sintilimab']
#asco22 abs#8516 interesting io + tki study in es-sclc presented by dr. ma, sintilimab + anlotinib in #lcsm es-sclc orr: 48.7% mpfs: 6 mths 12 mth os: 56% trae: 95% 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own